PD-1 gene engineered T cell therapy(Meijesell Biotechnology)

PD-1基因编辑T细胞（成都美杰赛尔）

Report date: 2025/07/02 17:51:41

Base Information

Drug NamePD-1 gene engineered T cell therapy(Meijesell Biotechnology)
Drug Alias NamePD-1敲出工程化T细胞（成都美杰赛尔）PD-1 knockout engineered T cells (Chengdu MedGenCell)PD-1敲除工程化T细胞（成都美杰赛尔）PD-1 knockout T cells (Chengdu MedGenCell)PD-1基因编辑T细胞
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWest China Hospital Of Sichuan UniversityChengdu Medgencell
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMeijesell (Beijing) Biotechnology Co LtdChengdu MedgencellSichuan University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A